Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
20
|
pubmed:dateCreated |
1990-11-21
|
pubmed:abstractText |
A panel of monoclonal antibodies against neural and epithelial associated antigens was used to examine bone marrow from patients in clinical remission from small cell lung cancer (SCLC). A standard peroxidase-antiperoxidase technique and Ficoll-Hypaque enrichment were used to detect SCLC-like cells at the 1-2% level of contamination in 8 of 12 patients who were disease free by conventional criteria, including routine marrow cytology and histology and endobronchoscopic biopsy or cytology. Six of these patients ultimately relapsed, with metastatic sites found between 2 and 6 months after restaging. Furthermore, 6 patients had undergone chemointensification including autologous marrow rescue with radical irradiation to the primary lung tumor. Four of these 6 subsequently relapsed, also with metastatic sites. Of the 4 patients without bone marrow metastases at restaging using this technique, 2 relapsed, with cells found at the primary site, and 2 remained in complete remission. Serum free cell culture was attempted in 9 of 12 cases and SCLC-like cell colonies grew, in suspension, in 4. The SCLC-like nature of these cells has been confirmed by electron microscopy in 1 case and by repeat immunocytochemistry for small cell associated antigens in 3 cases. Bone marrow positivity using these techniques appears to predict a high risk of metastatic relapse regardless of further therapy.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0008-5472
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
50
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
6545-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2170006-Adult,
pubmed-meshheading:2170006-Aged,
pubmed-meshheading:2170006-Antibodies, Monoclonal,
pubmed-meshheading:2170006-Bone Marrow,
pubmed-meshheading:2170006-Carcinoma, Small Cell,
pubmed-meshheading:2170006-Female,
pubmed-meshheading:2170006-Humans,
pubmed-meshheading:2170006-Immunohistochemistry,
pubmed-meshheading:2170006-Lung Neoplasms,
pubmed-meshheading:2170006-Male,
pubmed-meshheading:2170006-Middle Aged,
pubmed-meshheading:2170006-Neoplasm Metastasis,
pubmed-meshheading:2170006-Prognosis
|
pubmed:year |
1990
|
pubmed:articleTitle |
Immunocytological detection of residual marrow disease at clinical remission predicts metastatic relapse in small cell lung cancer.
|
pubmed:affiliation |
Imperial Cancer Research Fund Medical Oncology Unit, Western General Hospital, Edinburgh, Scotland.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|